Maternal transfer of neutralizing antibodies to B. burgdorferi OspA after oral vaccination of the rodent reservoir

We present new evidence for maternal transfer of oral vaccine induced neutralizing anti-OspA IgG antibodies to mouse pups mainly through ingestion of colostrum. We found a strong statistical correlation of antibody transfer between mothers that produced the most robust IgG response to OspA and their respective pups. OspA-specific antibody was detected as early as 24 h after birth and protective levels of antibodies lasted until ~5 weeks of age in the majority of pups but persisted in some mice until 9 weeks. This was further supported by detection of neutralizing antibodies in serum of all pups at 2-3 weeks after birth and in some offspring adult mice at 9 weeks of age. A clear association was found between robust antibody responses in mothers and the length of time antibody persisted in the respective pups using a novel longitudinal Bayesian model. These factors are likely to impact the enzootic cycle of B. burgdorferi if reservoir targeted OspA-based vaccination interventions are implemented.PMID:34172332 | DOI:10.1016/j.vaccine.2021.06.025
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research

Related Links:

Vaccine. 2022 Jan 13:S0264-410X(22)00006-8. doi: 10.1016/j.vaccine.2022.01.003. Online ahead of print.ABSTRACTVaccination guidelines for dogs and cats indicate that core vaccines (for dogs, rabies, distemper, adenovirus, parvovirus; for cats, feline parvovirus, herpes virus-1, calicivirus) are essential to maintain health, and that non-core vaccines be administered according to a clinician's assessment of a pet's risk of exposure and susceptibility to infection. A reliance on individual risk assessment introduces the potential for between-practice inconsistencies in non-core vaccine recommendations. A study was initiated t...
Source: Herpes - Category: Infectious Diseases Authors: Source Type: research
DISCUSSION: Overall, willingness to receive a Lyme disease vaccine was high. Effective communication by clinicians regarding safety and other vaccine parameters to those groups who are uncertain will be critical for increasing vaccine uptake and reducing Lyme disease incidence.PMID:34895785 | DOI:10.1016/j.vaccine.2021.11.065
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
NIH researcher Andaleeb Sajid discusses her study ’s finding that ticks were unable to feed on vaccinated guinea pigs, preventing transmission of the pathogen that causes Lyme disease.
Source: The Scientist - Category: Science Tags: News & Opinion Source Type: news
Could wildfires be depleting the ozone all over again? Staff Writer Paul Voosen talks with host Sarah Crespi about the evidence from the Polarstern research ship for wildfire smoke lofting itself high into the stratosphere, and how it can affect the ozone layer once it gets there. Next, we talk ticks—the ones that bite, take blood, and can leave you with a nasty infection. Andaleeb Sajid, a staff scientist at the National Cancer Institute, joins Sarah to talk about her Science Translational Medicine paper describing an mRNA vaccine intended to reduce the length of tick bites to before the pests can transmit diseases...
Source: Science Magazine Podcast - Category: Science Authors: Source Type: podcasts
An mRNA vaccine that causes a red, itchy skin rash in response to bites by ticks may allow them to be removed before they transmit Lyme disease-causing bacteria
Source: New Scientist - Health - Category: Consumer Health News Source Type: research
A Yale-developed vaccine that helps more quickly identify tick bites on guinea pigs could offer humans protection against Lyme Disease and other pathogens.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
In areas where Lyme disease is endemic, bites from ticks are common, but no vaccine is currently available against Lyme disease for humans. Therefore, the feasibility of using antibiotic prophylaxis to prevent...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Research Source Type: research
When health experts talk about the remarkable efficacy of COVID-19 vaccines, they typically point to their ability to prevent severe disease and death. Fully vaccinated people can still get “breakthrough” infections from the virus that causes COVID-19—but compared to an unvaccinated person, they’re more than 10 times less likely to be hospitalized or die from their illness, according to U.S. Centers for Disease Control and Prevention (CDC) research. Officials often point to these impressive figures as evidence that we can tame COVID-19 into a mostly mild illness that behaves like a routine cold or f...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Immunobiology. 2021 Jul 13;226(5):152091. doi: 10.1016/j.imbio.2021.152091. Online ahead of print.ABSTRACTThe spike protein of coronavirus is key target for drug development and other pharmacological interventions. In current study, we performed an integrative approach to predict antigenic sites in SARS-CoV-2 spike receptor binding domain and found nine potential antigenic sites. The predicted antigenic sites were then assessed for possible molecular similarity with other known antigens in different organisms. Out of nine sites, seven sites showed molecular similarity with 54 antigenic determinants found in twelve pathogen...
Source: Immunobiology - Category: Allergy & Immunology Authors: Source Type: research
More News: Allergy & Immunology | Grants | International Medicine & Public Health | Lyme Disease | Statistics | Vaccines